Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Drugging the intrinsically disordered transactivation domain of androgen receptor

Fig. 2The alternative text for this image may have been generated using AI.

Efficacy and IC50s to block endogenous expression of genes transcriptionally regulated by full-length AR. a LNCaP xenografts grown in castrated mice dosed by gavage daily with vehicle (VEH), BU27 (30 mg/kg), its matching analogue BU3-12 (30 mg/kg), and enzalutamide (10 mg/kg). b LNCaP xenografts grown in castrated mice dosed by gavage daily with vehicle (VEH), BU130 (30 mg/kg), its matching analogue BU170 (30 mg/kg), and enzalutamide (10 mg/kg). c mRNA levels of androgen-induced genes normalized to housekeeping gene SDHA from LNCaP cells. Data presented as mean ± SEM and normalized to DMSO vehicle control in presence of R1881 (n = 3 independent experiments). d Table showing IC50 values for each inhibitor for genes shown in c. The sum-of-squares F test was performed to compare IC50’s for each inhibitor against EPI-002 (ralaniten). e Transcript levels of androgen-repressed genes normalized to levels of housekeeping gene SDHA from LNCaP cells treated as in c. Data presented as mean ± SEM, and analyzed by one-way ANOVA with Dunnet’s correction (n = 3 independent experiments). ND: not detected. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Back to article page